We believe F5 stock (NASDAQ: FFIV), an application security and cloud networking company, and Teleflex stock (NYSE: TFX), best known for its single-use medical products for common diagnostic and ...

The stock price of Teleflex (NYSE:TFX), best known for its single-use medical devices for common diagnostic and therapeutic procedures, has seen a decline of 12% over the last month, while it was down ...

Teleflex stock (NYSE: TFX), best known for its single-use medical devices for common diagnostic and therapeutic procedures, has seen a 31% fall this year, underperforming the broader S&P500 index, ...

Teleflex’s TFX broad Vascular Access portfolio is poised to continue to win shares through its category leadership in Central Venous Catheters (CVC), midlines and new launches. The company’s expansion ...

The latest price target for Teleflex (NYSE:TFX) was reported by Truist Securities on May 5, 2025. The analyst firm set a price target for $137.00 expecting TFX to rise to within 12 months (a possible ...

Teleflex (TFX) has quietly become a talking point after another choppy week for medtech names, with the stock drifting lower over the past week even as the past month’s performance turned positive.

Teleflex (NYSE:TFX) is slated for expansion in the coming quarters, owing to the key growth drivers in the Interventional business. The company's market dominance in Central Venous Catheters and ...

Teleflex (NYSE:TFX – Free Report) had its price objective lowered by Mizuho from $150.00 to $130.00 in a research report released on Wednesday,Benzinga reports. The brokerage currently has a neutral ...

Teleflex stock (NYSE: TFX), which provides instruments and consumables for laboratories, trades at $220 per share, 50% below the level seen in March 2021. TFX stock was trading at around $246 in early ...

Teleflex’s TFX Interventional Urology portfolio is well positioned for sustained growth, led by UroLift’s expanding global footprint and strong clinical differentiation. Supported by favorable ...